Pre-made Obrindatamab benchmark antibody ( Bispecific scFv with Domain Crossover, anti-CD276;CD3E therapeutic antibody, Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-386

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-386 Category Tags ,

Product Details

Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Obrindatamab (formerly orlotamab) was a Fc-bearing humanised bispecific dual-affinity re-targeting (DART) protein, that was being developed by MacroGenics for the treatment of solid tumours.

Products Name (INN Index)

Pre-Made Obrindatamab biosimilar, Bispecific scFv with Domain Crossover, Anti-CD276;CD3E Antibody: Anti-4Ig-B7-H3/B7-H3/B7H3/B7RP-2;T3E/TCRE/IMD18 therapeutic antibody

INN Name

Obrindatamab

Target

CD276,CD3E

Format

Bispecific scFv with Domain Crossover

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

na;na

VD LC

Kappa,Lambda

Highest_Clin_Trial (Jan '20)

Phase-I

Est. Status

Discontinued

100% SI Structure

None;None

99% SI Structure

None;None

95-98% SI Structure

None;None

Year Proposed

2020

Companies

MacroGenics

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

Advanced or Metastatic solid tumours

Development Tech

Dual-Affinity?Re-targenting (DART?)

Previous Name

NA

Gm Offical Target Name

CD276,CD3E

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide